NEXI - Earnings announcements

GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report third quarter financial results and provide a corporate update on Friday, November 12, 2021, via press release, prior to the market open. The press release will be accessible under the investor section of the NexImmune's website at www.neximmune.com. About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the

GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report second quarter financial results and provide a corporate update on Monday, August 9, 2021, via press release, after market close. The press release will be accessible under the investor section of the NexImmune's website at www.neximmune.com. About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's